Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 9/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6155761 | 0.80 | SIGMAR1 (0.67) | EPHX2SIGMAR1EPHX1 | |
| SCHEMBL6156408 | 0.80 | SIGMAR1 (0.61) | EPHX2SIGMAR1HSD17B10L3MBTL1EPHX1 | |
| SCHEMBL6154324 | 0.74 | EPHX2 (0.44) | EPHX2SIGMAR1 | |
| SCHEMBL2740883 | 0.73 | SIGMAR1 (0.66) | EPHX2SIGMAR1EPHX1 | |
| SCHEMBL6154854 | 0.71 | SIGMAR1 (0.53) | EPHX2SIGMAR1L3MBTL1EPHX1 | |
| SCHEMBL6156210 | 0.70 | SIGMAR1 (0.58) | EPHX2SIGMAR1EPHX1 | |
| SCHEMBL6157187 | 0.68 | SIGMAR1 (0.62) | EPHX2SIGMAR1HSD17B10L3MBTL1EPHX1 | |
| SCHEMBL6155548 | 0.68 | SIGMAR1 (0.62) | EPHX2SIGMAR1EPHX1 | |
| SCHEMBL6154705 | 0.66 | SIGMAR1 (0.49) | EPHX2SIGMAR1HSD17B10L3MBTL1EPHX1 | |
| SCHEMBL6156206 | 0.65 | EPHX2 (0.64) | EPHX2SIGMAR1HSD17B10L3MBTL1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0940139-B1 | Substituted guanidines and derivatives thereof as modulators of neurotransmitter release and novel methodology for identifying neurotransmitter release blockers | SCION PHARMACEUTICALS INC (US) | 2005-02-02 | — | — | EP | claimed |
| EP-0940139-A2 | Substituted guanidines and derivatives thereof as modulators of neurotransmitter release and novel methodology for identifying neurotransmitter release blockers | CAMBRIDGE NEUROSCIENCE RESEARCH, INC. (US) | 1999-09-08 | — | — | EP | claimed |
| US-5837737-A | MODULATOR OF NEUROTRANSMITTERS | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1998-11-17 | — | — | US | claimed |
| US-5686495-A | Substituted hydrazinedicarboximidamides and methods of use thereof | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1997-11-11 | — | — | US | claimed |
| US-5652269-A | MODULATION OF NEUROTRANSMITTER RELEASE, NEUROPROTECTIVE | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1997-07-29 | — | — | US | claimed |
| US-5403861-A | Treating or preventing nerve cell death | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1995-04-04 | — | — | US | claimed |
| EP-0584088-A4 | SUBSTITUTED GUANIDINES AND DERIVATIVES THEREOF AS MODULATORS OF NEUROTRANSMITTER RELEASE AND NOVEL METHODOLOGY FOR IDENTIFYING NEUROTRANSMITTER RELEASE BLOCKERS. | CAMBRIDGE NEUROSCIENCE RES (US) | 1995-01-18 | — | — | EP | claimed |
| EP-0584088-A1 | SUBSTITUTED GUANIDINES AND DERIVATIVES THEREOF AS MODULATORS OF NEUROTRANSMITTER RELEASE AND NOVEL METHODOLOGY FOR IDENTIFYING NEUROTRANSMITTER RELEASE BLOCKERS | CAMBRIDGE NEUROSCIENCE RESEARCH, INC. (US) | 1994-03-02 | — | — | EP | claimed |
| WO-1992014697-A1 | SUBSTITUTED GUANIDINES AND DERIVATIVES THEREOF AS MODULATORS OF NEUROTRANSMITTER RELEASE AND NOVEL METHODOLOGY FOR IDENTIFYING NEUROTRANSMITTER RELEASE BLOCKERS | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1992-09-03 | — | — | WO | claimed |
| EP-0940139-B1 | Substituted guanidines and derivatives thereof as modulators of neurotransmitter release and novel methodology for identifying neurotransmitter release blockers | SCION PHARMACEUTICALS INC (US) | 2005-02-02 | — | — | EP | disclosed |
| US-6071969-A | ADMINISTERING AMINOGUANIDINE DERIVATIVE TO MAMMAL FOR TREATING OR PREVENTING DISEASE OF NERVOUS SYSTEM IN WHICH PATHOPHYSIOLOGY OF DISORDER INVOLVES EXCESSIVE RELEASE OF OF NEUROTRANSMITTER FROM NEURONAL CELLS | CAMBRIDGE NEUROSCIENCE, INC. (US) | 2000-06-06 | — | — | US | disclosed |
| EP-0584088-B1 | SUBSTITUTED GUANIDINES AND DERIVATIVES THEREOF AS MODULATORS OF NEUROTRANSMITTER RELEASE AND NOVEL METHODOLOGY FOR IDENTIFYING NEUROTRANSMITTER RELEASE BLOCKERS | CAMBRIDGE NEUROSCIENCE RES (US) | 1999-10-27 | — | — | EP | disclosed |
| EP-0940139-A2 | Substituted guanidines and derivatives thereof as modulators of neurotransmitter release and novel methodology for identifying neurotransmitter release blockers | CAMBRIDGE NEUROSCIENCE RESEARCH, INC. (US) | 1999-09-08 | — | — | EP | disclosed |
| US-5837737-A | MODULATOR OF NEUROTRANSMITTERS | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1998-11-17 | — | — | US | disclosed |
| US-5622968-A | ADMINISTERING TO BLOCK VOLTAGE SENSITIVE CALCIUM CHANNELS OF MAMMALIAN NEURONAL CELLS | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1997-04-22 | — | — | US | disclosed |
| US-5614630-A | NEUROTRANSMITTER RELEASE MODULATOR | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1997-03-25 | — | — | US | disclosed |
| US-5403861-A | Treating or preventing nerve cell death | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1995-04-04 | — | — | US | disclosed |
| EP-0584088-A4 | SUBSTITUTED GUANIDINES AND DERIVATIVES THEREOF AS MODULATORS OF NEUROTRANSMITTER RELEASE AND NOVEL METHODOLOGY FOR IDENTIFYING NEUROTRANSMITTER RELEASE BLOCKERS. | CAMBRIDGE NEUROSCIENCE RES (US) | 1995-01-18 | — | — | EP | disclosed |
| EP-0584088-A1 | SUBSTITUTED GUANIDINES AND DERIVATIVES THEREOF AS MODULATORS OF NEUROTRANSMITTER RELEASE AND NOVEL METHODOLOGY FOR IDENTIFYING NEUROTRANSMITTER RELEASE BLOCKERS | CAMBRIDGE NEUROSCIENCE RESEARCH, INC. (US) | 1994-03-02 | — | — | EP | disclosed |
| WO-1992014697-A1 | SUBSTITUTED GUANIDINES AND DERIVATIVES THEREOF AS MODULATORS OF NEUROTRANSMITTER RELEASE AND NOVEL METHODOLOGY FOR IDENTIFYING NEUROTRANSMITTER RELEASE BLOCKERS | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1992-09-03 | — | — | WO | disclosed |